Healthy Skepticism Library item: 16047
Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.
Publication type: Journal Article
Cohen D.
Academics criticise plan to allow new drugs to bypass NICE
BMJ. 2009 Jul 21; 339:
http://www.bmj.com/cgi/content/extract/339/jul21_2/b2938
Abstract:
Plans drawn up by the government to boost the life sciences industry have been criticised by some academics for eroding the cost effectiveness model of the National Institute for Health and Clinical Excellence (NICE) and for undermining academic impedance.
In their life sciences blueprint, innovative drugs will be approved for NHS use for a set period without having first gone through NICE’s appraisal process to allow data to build up to show cost effectiveness. After a predetermined period they will then go through the usual NICE appraisal process.
The so called innovation pass will be piloted in 2010-11, with a budget of £25m (29m; $41m), and then evaluated. Although what constitutes a successful pilot has yet to be decided, NICE will play a key role in developing and applying eligibility criteria for the pass and is set to enter discussions with industry and the NHS.
Mike Rawlins, chairman of . . .
